Website URL:
   Homepage

Accessibility links

     * Skip to content
     * Accessibility Help

   BBC Account
   Notifications
   
     * Home
     * News
     * Sport
     * Weather
     * iPlayer
     * Sounds
     * CBBC
     * CBeebies
     * Food
     * Bitesize
     * Arts
     * Taster
     * Local
     * TV
     * Radio
     * Three
     * Menu

   Search
   News 

BBC News Navigation

   
   Sections
   
     * Home 
     * Video 
     * World 
     * US & Canada 
     * UK 
     * Business  selected
     * Tech 
     * Science 
     * Stories 
     * Entertainment & Arts 
     * Health 
     * In Pictures 
     * Reality Check 
     * World News TV 
     * Newsbeat 
     * Special Reports 
     * Explainers 
     * The Reporters 
     * Have Your Say 

   Business selected
     * Market Data 
     * Global Trade 
     * Companies 
     * Entrepreneurship 
     * Technology of Business 
     * Connected World 
     * Global Education 
     * Economy 

   Business
   Business

Coronavirus: Will someone develop a vaccine?

   By Justin Harper Business reporter
     * 13 February 2020

     * Share this with Facebook 
     * Share this with Messenger 
     * Share this with Twitter 
     * Share this with Email 
     * Share this with Facebook 
     * Share this with WhatsApp 
     * Share this with Messenger 
     * Share this with Twitter 
     * Share 
       Share this with
       These are external links and will open in a new window
          + Email
            Share this with Email 
          + Facebook
            Share this with Facebook 
          + Messenger
            Share this with Messenger 
          + Messenger
            Share this with Messenger 
          + Twitter
            Share this with Twitter 
          + Pinterest
            Share this with Pinterest 
          + WhatsApp
            Share this with WhatsApp 
          + LinkedIn
            Share this with LinkedIn 
       Copy this link
       https://www.bbc.com/news/business-51454859
       Read more about sharing.
       These are external links and will open in a new window
       (BUTTON) Close share panel

   Related Topics
     * Coronavirus outbreak

   Employees working in a lab Image copyright Valery Matytsin Image caption Work to develop a vaccine for the coronavirus is continuing

   While the world worries about the spread of the deadly coronavirus, now known as Covid-19, one would expect the major pharmaceutical firms to make millions, even billions, by rushing to develop a vaccine.

   But in reality, this is not the case. While the global vaccine market is expected to grow to $60bn (£46bn) this year, big profits are not guaranteed.

   ''Successfully developing a preventive vaccine or treatment for a public health crisis is difficult. It typically takes a lot of time and money," says US-based Brad Loncar, a biotechnology investor and chief executive of Loncar Investments.

   "There is typically little money in it for companies that do successfully develop something, not the billions that some investors mistakenly expect."
     * Inside the lab developing a coronavirus vaccine - BBC News
     * China and the virus that threatens everything
     * Coronavirus disease named Covid-19

   The global vaccines industry is dominated by big players such as Pfizer, MSD, GlaxoSmithKline (GSK), Sanofi, and Johnson & Johnson.

   Worldwide sales of vaccines totalled $54bn last year, and have almost doubled since 2014, according to data analysts Statista. Driving this growth is the increase of infectious diseases like influenza, swine flu, hepatitis and Ebola.
   Image copyright Getty Images Image caption The coronavirus outbreak is far from contained

   "One would think that the industry has the reserves to jump at this challenge. But none of the four top vaccine companies has shown significant interest," says Dr Ellen 't Hoen, director at medicines law and policy at University Medical Center Groningen in Amsterdam.

   Outside of the big firms, there are a handful of smaller pharma companies pushing to find a vaccine for the deadly Covid-19 outbreak, which has already claimed more than 1,000 lives.

   Gilead, a US biotech business that makes anti-HIV drugs, has announced it will trial its drug Remdesivir. Meanwhile Kaletra, a combination of two anti-HIV drugs from pharma group AbbVie is being trialled on patients in China. Both trials are based on existing medicines.

   "A large company like Gilead or AbbVie will be able to use an existing medicine against this as a therapeutic treatment, but it's unlikely to be much of a needle mover from a stock market perspective for a large company like that," adds Mr Loncar.
   Image copyright Getty Images Image caption It is no guarantee that a pharma firm would make much money from making a vaccine

   For Covid-19, charitable donations are being used to spark pharma companies into action to find a vaccine. One of the leading players is a not-for-profit organisation called the Coalition for Epidemic Preparedness Innovations (CEPI).

   CEPI co-founders include the governments of Norway and India, the Bill and Melinda Gates Foundation, and the Wellcome Trust. CEPI is supporting vaccine development programmes by Inovio Pharmaceuticals and Moderna.

   Among the big pharma companies, GSK has agreed to make its technology available to the CEPI to help it create a medicine against Covid-19.

   Vaccines often require lengthy testing on thousands of people before they are allowed to be sold. But in 2002 and 2003, the Sars outbreak came and went before a vaccine could be produced. In fact, there is still no protective vaccine for Sars available.

   Regarding Ebola, the first vaccine was produced by MSD, and successfully deployed in Guinea, west Africa, in 2015. At the time it was an unlicensed drug, yet it was rolled out in the country for "compassionate use" after the authorisation of the Guinean government. MSD's vaccine was not given regulatory approval in the US until last year.

   Another Ebola vaccine by Johnson & Johnson was made available from 2019 in the Democratic Republic of Congo.

   Ronald Klain served as the US Ebola response coordinator in 2014-15. "I don't work for the companies, I'm not like a drug company fan," Mr Klain told a panel last week hosted by not-for-profit think-tank Aspen Institute, "but there's no question that a lot of them lost a lot of money trying to produce an Ebola vaccine."
   Image copyright Getty Images Image caption MSD's Ebola virus vaccine took five years to develop

   A key reason why vaccines often have to wait years before they are given regulatory approval is the potential for side effects. These can also happen even when a drug has been approved.

   During the 2009-10 swine flu pandemic, six million people were given the Pandemrix vaccine made by GlaxoSmithKline. However, it was subsequently withdrawn from sale after it was discovered to cause narcolepsy in some people. Narcolepsy is a sleep disorder that causes people to fall asleep numerous times a day.

   Also speaking at last week's Aspen Institute event, Dr Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, said no major pharmaceutical company has come forward to say it would manufacture a vaccine for Covid-19. He called it "very difficult and very frustrating".

   "Companies that have the skill to be able to do it are not going to just sit around and have a warm facility, ready to go for when you need it," Dr Fauci said.

Global Trade

   More from the BBC's series taking an international perspective on trade:
     * The women who make argan oil want better pay
     * What ancient Rome may teach on post-Brexit tourism
     * 'I have to live on $1,175 a year'
     * Why is kosher food soaring in popularity? 
     * As the ice melts, Greenland considers its future

   Dr Fauci added that it would be at least one year before a Covid-19 vaccine would be available. That timeline assumes a large pharma manufacturer steps up to help make the product. The World Health Organization (WHO) hopes a vaccine will be ready within 18 months.

   Pharma companies have responded to previous public health crises by developing vaccines, only to have those crises fade, and to be left with significant research and development costs. "When we were doing this with Ebola, it was a major vaccine company that got burned who's now pulling out of that," says Dr Fauci. "It is going to be a challenge to be able to get a major company to do that."

   Mr Loncar sums up the mentality of the big pharma firms when he said "most companies and investors are not in these things for the long haul".

Related Topics

     * Pharmaceutical industry
     * Coronavirus outbreak
     * Public health
     * Bill Gates
     * Vaccination
     * Medicine
     * Ebola treatments

Share this story About sharing

     * Email 
     * Facebook 
     * Messenger 
     * Messenger 
     * Twitter 
     * Pinterest 
     * WhatsApp 
     * LinkedIn 

Top Stories

   Venice Carnival closes amid coronavirus outbreak

   Italy quarantines whole towns, closes schools and cancels sports fixtures as infections increase.
   23 February 2020
    Medical masks at Philippines mass wedding
   23 February 2020
    Nevada caucuses: Who won and who lost?
   23 February 2020
   

Features

   

Dead within three hours of arrival at a Russian prison

   
   

Dubs or subs? Parasite renews the debate

   
   

Nevada - winners and losers

   
   
   Video

Hip-hop's iconic photos go on display

   
   

Wallis Simpson's hard lessons for Harry and Meghan

   
   

The potential diplomatic impact of coronavirus

   
   

What will Trump's visit do for US-India ties?

   
   
   Video

Simone Biles on abuse, race and life after gymnastics

   
   

Could the Big Bang have created a hidden 'twin' Universe?

   

Elsewhere on the BBC

   

Football phrases

   

   15 sayings from around the world
   Full article Football phrases
   Why you can trust BBC News

BBC News Navigation

   Business Sections
     * Market Data
     * Global Trade
     * Companies
     * Entrepreneurship
     * Technology of Business
     * Connected World
     * Global Education
     * Economy

     * Home 
     * Video 
     * World 
          + World Home
          + Africa
          + Asia
          + Australia
          + Europe
          + Latin America
          + Middle East
     * US & Canada 
          + US & Canada Home
     * UK 
          + UK Home
          + England
          + N. Ireland
          + Scotland
          + Wales
          + Politics
     * Business  selected
          + Business Home
          + Market Data
          + Global Trade
          + Companies
          + Entrepreneurship
          + Technology of Business
          + Connected World
          + Global Education
          + Economy
     * Tech 
     * Science 
     * Stories 
     * Entertainment & Arts 
     * Health 
     * In Pictures 
     * Reality Check 
     * World News TV 
     * Newsbeat 
     * Special Reports 
     * Explainers 
     * The Reporters 
     * Have Your Say 

BBC News Services

     * On your mobile
     * On smart speakers
     * Get news alerts
     * Contact BBC News

Explore the BBC

     * Home
     * News
     * Sport
     * Weather
     * iPlayer
     * Sounds
     * CBBC
     * CBeebies
     * Food
     * Bitesize
     * Arts
     * Taster
     * Local
     * TV
     * Radio
     * Three

     * Terms of Use
     * About the BBC
     * Privacy Policy
     * Cookies
     * Accessibility Help
     * Parental Guidance
     * Contact the BBC
     * Get Personalised Newsletters

   Copyright © 2020 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.